Cannabis use associated with reduced risk of cancer in patients with Crohn’s disease

September 13, 2019
crohns_disease-1200x900.jpg

The association of cannabis with the reduction of developmental colorectal cancer

Case studies suggest that there is an anti-inflammatory agent in cannabis. 

One study found a link between cannabis use and a lower risk of colon cancer, anaemia and hospitalisation.

The nationwide inpatient sample data sets (2010-2014) were examined to identify adults with crohn’s disease (CD) and ulcerative colitis (UC). 

Recent studies about Crohn’s disease and Cannabis

This is the result of a study conducted by Atlanta VA Medical Center in Decatur, USA:

The study examined 6,002 patients  with CD (2,999 cannabis users & 3,003 non-users) and 1,481 patients with UC (742 cannabis users & 739 non-users). 

In patients with CD, the presence of colorectal cancer, the need for parenteral nutrition, and anemia were lower in cannabis users. 

However, active fistula disease or intra-abdominal abscess formation, non-specific bleeding in the lower gastrointestinal tract and hypovolemia were higher in recreational cannabis use. 

Additionally, the average hospital stay was shorter with lower hospital costs among cannabis users.

 

Source: Cannabis-med

Image: AGMG

Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

footerlogos

OFFICES

CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg
Germany

IberCanPharma LDA
Rua João Fernandes
Lavrador 1 – Sala 6 2825-
132 Vila Nova de Caparica
Portugal

REPRESENTATIVE OFFICES

Berlin
Neue Kantstraße 18
14057 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain